Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET/CT: preliminary report of in six patients.

about

Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET/CT: preliminary report of in six patients.

Item

http://www.wikidata.org/entity/Q41558340

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Somatostatin receptors over-ex ...... ary report of in six patients.

@en

type

Item

label

Somatostatin receptors over-ex ...... ary report of in six patients.

@en

prefLabel

Somatostatin receptors over-ex ...... ary report of in six patients.

@en

P1476

Somatostatin receptors over-ex ...... ary report of in six patients.

@en

P2093

Alberto Zaniboni

http://www.w3.org/2001/XMLSchema#string

Alfredo Muni

http://www.w3.org/2001/XMLSchema#string

Camilla Casi

http://www.w3.org/2001/XMLSchema#string

Chiara Minari

http://www.w3.org/2001/XMLSchema#string

Giordano Savelli

http://www.w3.org/2001/XMLSchema#string

Giuseppe Valmadre

http://www.w3.org/2001/XMLSchema#string

Pierluigi Rossini

http://www.w3.org/2001/XMLSchema#string

Roberta Falchi

http://www.w3.org/2001/XMLSchema#string

Roberto Barbieri

http://www.w3.org/2001/XMLSchema#string

P2860

Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse

Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients

The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.

Castration-resistant prostate cancer: AUA Guideline.

[111In-DTPA-D-Phe1]-octreotide scintigraphy in patients with hormone-refractory prostatic adenocarcinoma can predict therapy outcome with octreotide treatment: a pilot study.

Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.

68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors.

Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression.

P304

145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2305-5839.2015.06.10

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26207238

http://www.w3.org/2001/XMLSchema#string

P932

4486921

http://www.w3.org/2001/XMLSchema#string